RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Biotechnology Assets Stock

Biotechnology Assets Stocks 2024

Biotechnology Assets Stocks

57.73 M

Ticker

BST.MC

ISIN

ES0184980003

WKN

A1XB95

In 2024, Biotechnology Assets had 57.73 M outstanding stocks, a 6.5% change from the 54.2 M stocks in the previous year.

The Biotechnology Assets Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
202357.73
202254.2
202145.61
202039.19
201939.17
201839.18
20175.09
20165.09
20154.63
20144.6
20134.21
20124.08
20113.86
20103.86

Biotechnology Assets shares outstanding

The number of shares was Biotechnology Assets in 2023 — This indicates how many shares 57.726 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Biotechnology Assets earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Biotechnology Assets's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Biotechnology Assets’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Biotechnology Assets's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Biotechnology Assets Aktienanalyse

What does Biotechnology Assets do?

ADL Bionatur Solutions SA is a Swiss company specializing in the development and production of natural ingredients for the food, cosmetics, and pharmaceutical industries. The company was founded in 2000 and has since had an impressive success story. ADL Bionatur Solutions SA's business model is based on the use of plants and microorganisms to extract high-quality natural active ingredients. The company employs environmentally friendly methods and sustainable production practices that meet the needs of society and nature alike. One of ADL Bionatur Solutions SA's main sectors is the production of natural flavors and colorants for the food industry. Depending on customer preferences, color pigments are extracted from fruits, vegetables, or other plants to color food products with natural ingredients. Natural flavors are also isolated using plant extracts and other natural sources. These products are particularly sought after because they are not only healthier than synthetic alternatives but also provide consumers with a better feeling. Another significant sector of ADL Bionatur Solutions SA is the development of cosmetics based on natural ingredients. For example, extracts from algae, flowers, or herbs are used to create skincare products that are gentle on the skin while still being highly effective. Products targeting signs of aging or acne are also based on natural ingredients from ADL Bionatur Solutions SA. In addition to these two main sectors, ADL Bionatur Solutions SA also offers products for the pharmaceutical industry. The company focuses on developing active ingredients based on natural substances that can be used to treat various diseases. Sustainability is also a key focus here, as naturally derived active ingredients are not only healthier but also have a higher biological availability. In addition to these main sectors, ADL Bionatur Solutions SA provides consulting services to customers. This includes the development of tailored natural solutions and support for product certification according to the highest international standards. Overall, in recent years, ADL Bionatur Solutions SA has become one of the world's leading companies in the field of natural ingredients. With a wide portfolio of products and services and a strong focus on sustainability and environmental compatibility, the company is well-positioned to benefit from the ongoing trend towards natural and healthier products. Biotechnology Assets ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Biotechnology Assets's Shares Outstanding

Biotechnology Assets's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Biotechnology Assets’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Biotechnology Assets’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Biotechnology Assets’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Biotechnology Assets stock

How many stocks are there of Biotechnology Assets?

The current number of stocks of Biotechnology Assets is 57.73 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Biotechnology Assets are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Biotechnology Assets evolved in recent years?

The number of shares of Biotechnology Assets has increased by 6.5% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Biotechnology Assets as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Biotechnology Assets?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Biotechnology Assets pay?

Over the past 12 months, Biotechnology Assets paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Biotechnology Assets is expected to pay a dividend of 0 EUR.

What is the dividend yield of Biotechnology Assets?

The current dividend yield of Biotechnology Assets is .

When does Biotechnology Assets pay dividends?

Biotechnology Assets pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Biotechnology Assets?

Biotechnology Assets paid dividends every year for the past 0 years.

What is the dividend of Biotechnology Assets?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Biotechnology Assets located?

Biotechnology Assets is assigned to the 'Health' sector.

Wann musste ich die Aktien von Biotechnology Assets kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Biotechnology Assets from 10/1/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Biotechnology Assets pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Biotechnology Assets in the year 2023?

In the year 2023, Biotechnology Assets distributed 0 EUR as dividends.

In which currency does Biotechnology Assets pay out the dividend?

The dividends of Biotechnology Assets are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Biotechnology Assets

Our stock analysis for Biotechnology Assets Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Biotechnology Assets Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.